Cargando…

Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells

[Image: see text] Hypoxic areas are present in the majority of solid tumors, and hypoxia is associated with resistance to therapies and poor outcomes. A transmembrane protein that is upregulated by tumor cells that have adapted to hypoxic conditions is carbonic anhydrase IX (CAIX). Therefore, noninv...

Descripción completa

Detalles Bibliográficos
Autores principales: van Lith, Sanne A.M., Huizing, Fokko J., Franssen, Gerben M., Hoeben, Bianca A.W., Lok, Jasper, Doulkeridou, Sofia, Boerman, Otto C., Gotthardt, Martin, van Bergen en Henegouwen, Paul M.P., Bussink, Johan, Heskamp, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533306/
https://www.ncbi.nlm.nih.gov/pubmed/35044182
http://dx.doi.org/10.1021/acs.molpharmaceut.1c00841
_version_ 1784802316755402752
author van Lith, Sanne A.M.
Huizing, Fokko J.
Franssen, Gerben M.
Hoeben, Bianca A.W.
Lok, Jasper
Doulkeridou, Sofia
Boerman, Otto C.
Gotthardt, Martin
van Bergen en Henegouwen, Paul M.P.
Bussink, Johan
Heskamp, Sandra
author_facet van Lith, Sanne A.M.
Huizing, Fokko J.
Franssen, Gerben M.
Hoeben, Bianca A.W.
Lok, Jasper
Doulkeridou, Sofia
Boerman, Otto C.
Gotthardt, Martin
van Bergen en Henegouwen, Paul M.P.
Bussink, Johan
Heskamp, Sandra
author_sort van Lith, Sanne A.M.
collection PubMed
description [Image: see text] Hypoxic areas are present in the majority of solid tumors, and hypoxia is associated with resistance to therapies and poor outcomes. A transmembrane protein that is upregulated by tumor cells that have adapted to hypoxic conditions is carbonic anhydrase IX (CAIX). Therefore, noninvasive imaging of CAIX could be of prognostic value, and it could steer treatment strategies. The aim of this study was to compare variants of CAIX-binding VHH B9, with and without a C-terminal albumin-binding domain with varying affinity (ABD(low) and ABD(high)), for SPECT imaging of CAIX expression. The binding affinity and internalization of the various B9-variants were analyzed using SK-RC-52 cells. Biodistribution studies were performed in mice with subcutaneous SCCNij153 human head and neck cancer xenografts. Tracer uptake was determined by ex vivo radioactivity counting and visualized by SPECT/CT imaging. Furthermore, autoradiography images of tumor sections were spatially correlated with CAIX immunohistochemistry. B9-variants demonstrated a similar moderate affinity for CAIX in vitro. Maximal tumor uptake and acceptable tumor-to-blood ratios were found in the SCCNij153 model at 4 h post injection for [(111)In]In-DTPA-B9 (0.51 ± 0.08%ID/g and 8.1 ± 0.85, respectively), 24 h post injection for [(111)In]In-DTPA-B9-ABD(low) (2.39 ± 0.44%ID/g and 3.66 ± 0.81, respectively) and at 72 h post injection for [(111)In]In-DTPA-B9-ABD(high) (8.7 ± 1.34%ID/g and 2.43 ± 0.15, respectively)(.) An excess of unlabeled monoclonal anti-CAIX antibody efficiently inhibited tumor uptake of [(111)In]In-DTPA-B9, while only a partial reduction of [(111)In]In-DTPA-B9-ABD(low) and [(111)In]In-DTPA-B9-ABD(high) uptake was found. Immunohistochemistry and autoradiography images showed colocalization of all B9-variants with CAIX expression; however, [(111)In]In-DTPA-B9-ABD(low) and [(111)In]In-DTPA-B9-ABD(high) also accumulated in non-CAIX expressing regions. Tumor uptake of [(111)In]In-DTPA-B9-ABD(low) and [(111)In]In-DTPA-B9-ABD(high), but not of [(111)In]In-DTPA-B9, could be visualized with SPECT/CT imaging. In conclusion, [(111)In]In-DTPA-B9 has a high affinity to CAIX and shows specific targeting to CAIX in head and neck cancer xenografts. The addition of ABD prolonged plasma half-life, increased tumor uptake, and enabled SPECT/CT imaging. This uptake was, however, partly CAIX- independent, precluding the ABD-tracers for use in hypoxia quantification in this tumor type.
format Online
Article
Text
id pubmed-9533306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-95333062022-10-06 Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells van Lith, Sanne A.M. Huizing, Fokko J. Franssen, Gerben M. Hoeben, Bianca A.W. Lok, Jasper Doulkeridou, Sofia Boerman, Otto C. Gotthardt, Martin van Bergen en Henegouwen, Paul M.P. Bussink, Johan Heskamp, Sandra Mol Pharm [Image: see text] Hypoxic areas are present in the majority of solid tumors, and hypoxia is associated with resistance to therapies and poor outcomes. A transmembrane protein that is upregulated by tumor cells that have adapted to hypoxic conditions is carbonic anhydrase IX (CAIX). Therefore, noninvasive imaging of CAIX could be of prognostic value, and it could steer treatment strategies. The aim of this study was to compare variants of CAIX-binding VHH B9, with and without a C-terminal albumin-binding domain with varying affinity (ABD(low) and ABD(high)), for SPECT imaging of CAIX expression. The binding affinity and internalization of the various B9-variants were analyzed using SK-RC-52 cells. Biodistribution studies were performed in mice with subcutaneous SCCNij153 human head and neck cancer xenografts. Tracer uptake was determined by ex vivo radioactivity counting and visualized by SPECT/CT imaging. Furthermore, autoradiography images of tumor sections were spatially correlated with CAIX immunohistochemistry. B9-variants demonstrated a similar moderate affinity for CAIX in vitro. Maximal tumor uptake and acceptable tumor-to-blood ratios were found in the SCCNij153 model at 4 h post injection for [(111)In]In-DTPA-B9 (0.51 ± 0.08%ID/g and 8.1 ± 0.85, respectively), 24 h post injection for [(111)In]In-DTPA-B9-ABD(low) (2.39 ± 0.44%ID/g and 3.66 ± 0.81, respectively) and at 72 h post injection for [(111)In]In-DTPA-B9-ABD(high) (8.7 ± 1.34%ID/g and 2.43 ± 0.15, respectively)(.) An excess of unlabeled monoclonal anti-CAIX antibody efficiently inhibited tumor uptake of [(111)In]In-DTPA-B9, while only a partial reduction of [(111)In]In-DTPA-B9-ABD(low) and [(111)In]In-DTPA-B9-ABD(high) uptake was found. Immunohistochemistry and autoradiography images showed colocalization of all B9-variants with CAIX expression; however, [(111)In]In-DTPA-B9-ABD(low) and [(111)In]In-DTPA-B9-ABD(high) also accumulated in non-CAIX expressing regions. Tumor uptake of [(111)In]In-DTPA-B9-ABD(low) and [(111)In]In-DTPA-B9-ABD(high), but not of [(111)In]In-DTPA-B9, could be visualized with SPECT/CT imaging. In conclusion, [(111)In]In-DTPA-B9 has a high affinity to CAIX and shows specific targeting to CAIX in head and neck cancer xenografts. The addition of ABD prolonged plasma half-life, increased tumor uptake, and enabled SPECT/CT imaging. This uptake was, however, partly CAIX- independent, precluding the ABD-tracers for use in hypoxia quantification in this tumor type. American Chemical Society 2022-01-19 2022-10-03 /pmc/articles/PMC9533306/ /pubmed/35044182 http://dx.doi.org/10.1021/acs.molpharmaceut.1c00841 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle van Lith, Sanne A.M.
Huizing, Fokko J.
Franssen, Gerben M.
Hoeben, Bianca A.W.
Lok, Jasper
Doulkeridou, Sofia
Boerman, Otto C.
Gotthardt, Martin
van Bergen en Henegouwen, Paul M.P.
Bussink, Johan
Heskamp, Sandra
Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
title Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
title_full Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
title_fullStr Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
title_full_unstemmed Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
title_short Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells
title_sort novel vhh-based tracers with variable plasma half-lives for imaging of caix-expressing hypoxic tumor cells
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533306/
https://www.ncbi.nlm.nih.gov/pubmed/35044182
http://dx.doi.org/10.1021/acs.molpharmaceut.1c00841
work_keys_str_mv AT vanlithsanneam novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT huizingfokkoj novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT franssengerbenm novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT hoebenbiancaaw novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT lokjasper novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT doulkeridousofia novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT boermanottoc novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT gotthardtmartin novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT vanbergenenhenegouwenpaulmp novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT bussinkjohan novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells
AT heskampsandra novelvhhbasedtracerswithvariableplasmahalflivesforimagingofcaixexpressinghypoxictumorcells